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Background: Bcl-2 plays a major role in the pathobiology and drug resistance of ovarian cancer, and inhibition of
bcl-2 was useful for OC therapy. It has previously reported that TW-37, a small-molecule inhibitor of Bcl-2 family
proteins, inhibited cell growth and induced apoptosis in many cancer cells. In the present study,we investigate the
effect of TW-37 or / and in combination with cisplain on several ovarian cancer (OC) cell lines with high bcl-2
expression.
Methods: The bcl-2 mRNA and protein expression, and the cisplain (DDP) sensitivity of OC cell lines SKOV3,
OVCAR3, OV-90 and 3AO and SKOV3DDP were determined by Quantitative real-time RT-PCR,Western blot, and
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and fluorescence-activated cell sorting (MTT) assays.
The effects of TW-37 alone or combined with cisplain on growth and apoptosis in bcl-2 overexpressed OVCAR3,
OV-90 and SKOV3DDP cells was detected by MTT,clonogenic assay, ELISA and terminal deoxynucleotidyl
transferase-mediated nick end labeling (TUNEL) assay.
Results: The cell lines SKOV3 and 3AO were sensitive, whereas OVCAR3, OV-90 and SKOV3DDP were resistant to
cisplain. Significant positive correlation was observed between basal bcl-2 mRNA and protein and cisplain sensitivity.
Cisplain treatment did not activate bcl-2 in vitro. Treatment with TW-37 inhibited bcl-2 expression in bcl-2
overexpressed OVCAR3, OV-90 and SKOV3DDP cells , and inhibited growth and induced apoptosis ,and increased
cisplain killing of the bcl-2 overexpressed cells in a does and time-dependant manner in vitro.
Conclusion: Bcl-2 level positively correlated with sensitivity to cisplain. Treatment with TW-37 was effective
alone and in combination with cisplain in bcl-2 overexpressed OC cell lines in vitro. Thus, TW-37 may be a useful
therapeutic agent for OCs.
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Ovarian carcinoma (OC) continues to be the leading
cause of death due to gynecologic malignancy in the
world because it is usually diagnosed in the advanced
stage of the disease [1,2]. The standard treatment for
epithelial ovarian cancer remains surgical debulking and
chemotherapy with a platinum and taxane agent. Al-
though many patients with disseminated tumors re-
spond initially to standard combinations of surgical* Correspondence: wfyxydrz1124@126.com
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currence [3].
Cisplatin (DDP) and its analogues are first-line chemo-
therapeutic agents for the treatment of human ovarian
cancer [4,5]. Cisplatin promotes its cytotoxicity by form-
ing DNA-protein cross-links, DNA mono-adducts, and
intrastrand DNA cross-links, which all trigger apoptosis
[6,7]. In ovarian cancer, the majority of tumours acquire
drug resistance. Response rates to first-line platinum-
based therapy are more than 80%, but most patients with
advanced disease will finally relapse and die because of ac-
quired drug resistance [8]. The mechanisms involved in
cisplatin resistance are not yet fully understood.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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shown to overexpress the Bcl-2 and/or its family mem-
bers [9-12]. Tumors expressing high levels of Bcl-2,
Mcl-1, or Bcl-XL, are often found to be resistant to che-
motherapeutic agents or radiation therapy [13]. There-
fore, novel avenues by which Bcl-2 could be inactivated
represent a promising strategy for the development of
novel and selective anticancer therapies. The Bcl-2 fam-
ily members are important proteins that regulate the
program cell death in cancer cell lines. It includes both
death antagonists such as Bcl-2, Bcl-XL and Mcl-1 as
well as death agonists such as Bax, Bak, Bid and Bad
[14]. An imbalance between antiapoptotic proteins (such
as Bcl-2, Bcl-XL and Mcl-1) and proapoptotic proteins
(such as Bax and Bcl-xs) is involved in the distinctive
biological features of adenocarcinomas [15].In epithelial
ovarian cancer, anti-apoptosis proteins Bcl-2, Bcl-XL and
Mcl-1 are highly over-expressed [9-12]. Clinical data
showed that the enhanced expression of Bcl-2 and Bcl-
XL is related to a shorter patient survival, whereas the
upregulation of Bax is associated with longer survival
and these findings suggest that the modulation of apop-
totic pathways might be one of the reasons why epithe-
lial ovarian cancer shows only limited sensitivity to
anticancer treatment [10-12]. Thus, blockade of Bcl-2
activity represents a novel and promising strategy for de-
signing new class of anticancer drugs that can overcome
the resistance of cancer cells to chemotherapy or
radiation.
TW-37 is a potent small-molecule inhibitor of BCL-2,
which attenuates BCL-2 activation and inhibits multiple
BCL-2 family members including BCL-XL and MCL-1.
It binds to the BCL-2 homology domain 3 (BH3) groove
of BCL-2 preventing the heterodimerization of proapop-
totic proteins (such as Bid, Bim, and Bad) with BCL-2
and subsequently allowing them to induce apoptosis
[16]. Recent studies indicate TW-37 is able to inhibit the
growth of a broad range of cancer cells, since it induces
S-phase cell cycle arrest with regulation of several im-
portant cell cycle related genes, including p27, p57, E2F-
1, cdc25A, CDK4, cyclin A, cyclin D1 and cyclin E
[17,18].
Thus, in the present study, we investigated whether
TW-37-induced inhibition of epithelial ovarian cancer
growth could be attributed to Bcl-2 inactivation in vitro,
and whether TW-37 increased the sensitivity of ovarian
cancer cells to DDP.
Materials and methods
Cell culture
Ovarian cancer cell lines SKOV3, OVCAR3, OV-90 and
3AO were obtained from the American Type Culture
Collection (ATCC; Shanghai, China). Cisplatin (DDP) re-
sistant SKOV3 cell line (SKOV3DDP) was obtained fromyiyeqi.cc (Shanghai, China). The cell lines were grown in
RPMI 1640 (Invitrogen) supplemented with 10% FBS.
SKOV3DDP was dissolved in DMSO (Novaplus, Ben
Venus Laboratories, Inc.) was added.Chemicals
Cisplatin (DDP, cis-diammine-dichloro-platinum II) and
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazo-
lium bromide] were purchased from Sigma-Aldrich (St.
Louis, MO). Stock DDP solution was prepared in DMSO
(330 mM), stored as aliquots at 20°C, and used within
2 weeks. DDP was further diluted in medium before
adding to the cells. TW-37 was obtained from Selleck
Chemicals Co. (Shanghai, China).Cytotoxicity assay
The microculture tetrazolium assay was used to measure
cytotoxicity as described earlier [19]. Treatment consisted
of continuous incubation with cisplatin (Pharmacochemie
BV, Haarlem, the Netherlands) or WT-37 for 96 h. The
mean IC50 ± s.d. was determined in three experiments,
each performed in quadruplicate.Cell growth inhibition assay by MTT assay
Cells were seeded in 96-well plates at 5 × 103 per well
and treated with varied concentrations (250 nmol/L,
500 nmol/L, and 750 nmol/L) of TW-37 for different
times (24 hs, 48 hs and 72 hs). After treatment, cell
densities were determined by the MTT assay. The results
were plotted as means ± SD of 3 separate experiments
having four determinations per experiment for each ex-
perimental condition. In addition to the above assay, we
have also done clonogenic assay for assessing the effects
of treatment as shown below.Soft-agar colony assay
Cells were plated (50,000–100,000 per well) in a six-well
plate and incubated overnight at 37°C. After 72-h expos-
ure to various concentrations of TW-37, then the cells
were plated in soft-agar at 37°C. The colonies in the soft
agar were counted in all untreated and treated wells
after 12 days as described before [20].Quantification of apoptosis by ELISA
The cell death detection ELISA (enzyme linked im-
munosorbent assay) kit was used for assessing apop-
tosis according to the manufacturer’s protocol. Briefly,
cells were treated with TW-37 for different periods of
time. After treatment, the cells were lysed and the cell
lysates were overlaid and incubated in microtiter plate
modules coated with antihistone antibody for detection
of apoptosis.
Figure 1 Western blot and Q-RT-PCR assay for bcl-2 protein and mRNA in SKOV3, OVCAR3, OV-90,3AO and SKOV3DDPovarian cancers
cell lines. bcl-2 protein and mRNA was highest in DDP resistant SKOV3 cell (SKOV3DDP).The experiments are repeated for three times. The
representative figs were shown. A, Western blot; B, Q-RT-PCR.
Figure 2 Ovarian cancer cells have differing levels of native
resistance to cisplatin. Human OC cell lines SKOV3, OVCAR3, OV-90,
3AO and SKOV3DDP were treated with increasing concentrations of
cisplatin (0–500 umol/L) for 72 h. The viabilities indicated on the y axis
were determined by MTT assays and normalized to control. Data
shown are means ± SE for n = 3 independent experiments.
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Cells were treated with TW-37 for 72 h, as described
above. After treatment, cells were washed with cold PBS
and fixed in ethanol for 1 h. The cells were then stained
with 5 μg/mL Hoechst for 30 min and visualized under
a fluorescence microscope. Bright condensed, punctuate,
or granular nuclei were considered apoptotic. Moreover,
terminal deoxynucleotidyltransferase-mediated nick end
labeling (TUNEL) was assayed with a commercial apop-
tosis detection kit (Promega Corp.)[17].
Western blot assay
Cells treated with different concentrations of cisplatin or
or/and TW-37, sonicated three times, cleared by centri-
fugation at 10,000 × g for 10 minutes at 4°C, and immu-
noblotted using antibodies for Bcl-2 and β-actin. Data
were expressed as relative fold expression overβ-actin.
Quantitative real-time RT-PCR
Real-time RT-PCR for bcl-2 and housekeeping gene
GAPDH was done using iScript One-Step RT-PCR kit with
SYBR Green (Bio-Rad), according to the manufacturer's in-
structions.The primer sequences used were as follows:
bcl-2 forward primer 5’-CTCCTGACGCTAAGAGCT
TCG-3’ , reverse primer 5’-CCAGGCTGGAAGGGAAAG
AC-3’;GAPDH forward primer 5’-CCTGGCACCCAGC
ACAAT-3’ , reverse primer 5’-GGGCCGGACTCGTCA
TCG-3’.
Statistical analysis
All data are presented as the mean ± SD. The data were
examined using analysis of variance (ANOVA) and the
least significant differences method for multisample
comparisons or Student’s t-test for two sample compari-
sons. P < 0.05 was considered as statistically significant.
Results
Bcl-2 is overexpressed in ovarian cancer cell lines
Using total RNAs and proteins from SKOV3, OVCAR3,
OV-90 , 3AO and SKOV3DDPovarian cancers cell lines,we show using real-time RT-PCR and immunoblotting
that all ovarian cancer cell lines, except SKOV3 VO-90
and 3AO, express higher levels of bcl-2 mRNA and
protein, respectively. SKOV3DDPovarian cancers cell
expressed the highest bcl-2 levels (Figure 1A and B).Ovarian cancer cell lines vary in resistance to DDP
SKOV3, OVCAR3, OV-90, 3AO and SKOV3DDP were
treated with different concentrations of cisplatin (1,
5,10,25,50 ,100 and 500 μmol/L) for 72 hours and the
number of surviving cells was analyzed. Whereas the cis-
platin LD50 was around 10 μmol/L −50 μmol/L for 3AO
and SKOV3 cell lines, which has very low bcl-2 levels.
The cisplatin LD50 was around 100 μmol/L for
OVCAR3 and OV-90, and > 500 μmol/L for SKOV3DDP
cell lines, which has highest bcl-2 levels (Figure 2).The
same sensitivities were obtained when the effects of cis-
platin were analyzed on apoptosis using TUNEL and
ELISA (data not shown). Therefore, we hypothesized
that bcl-2 mRNA or protein levels would predict che-
moresistance. These data supported the classification of
the SKOV3 and 3AO cell lines as cisplatin-sensitive, and
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resistance.
Cisplatin treatment did not affect bcl-2 mRNA and protein
level
Although basal bcl-2 level reflect cisplain sensitivity, it
remained possible that responses to stress may be differ-
ent in sensitive versus resistant cells. Therefore, we
wished to evaluate whether bcl-2 in response to treat-
ment with cisplain could predict sensitivity. SKOV3,
OVCAR3, OV-90, 3AO and SKOV3DDP were stimu-
lated with various concentrations of cisplain (1 μmol/
L-500 μmol/L) for 24 hours in vitro and bcl-2 mRNAFigure 3 Effect of TW-37 on bcl-2 expression and growth in OVCAR3,
SKOV3DDP cells for 1–3 days with 250, 500 and 750 nM of TW-37. (A) Dose
and SKOV3DDP cells by western blot assay. (B) Dose and time responses of
are means ± SE for n = 3 independent experiments. Vs control, *P < 0.05.and protein were measured using Q-PCR and western
blot assay.Cisplain (1 μmol/L-500 μmol/L) treatment
for 24 hours had no significant effect on bcl-2 level in
any of the cells analyzed (Data not shown).
TW-37-induced cell growth inhibition by MTT assay
We next examined the growth inhibitory effects of
TW-37 using the MTT assay in 3 OC cell lines such as
OVCAR3, OV-90 and SKOV3DDP. The reason for
choosing these 3 OC cell lines was due to the fact that
these cell lines showed higher expression of Bcl-2. The
treatment of OC cells for 1–3 days with 250, 500 and
750 nM of TW-37,the bcl-2 was significantly inhibitedOV-90 and SKOV3DDP cells. The treatment of OVCAR3, OV-90 and
and time responses of TW-37 on bcl-2 inhibition in OVCAR3, OV-90
TW-37 on growth of OVCAR3, OV-90 and SKOV3DDP cells. Data shown
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time-dependent manner in all 3 OC cell lines (Figure 3B)
In addition, we have also tested the effects of treatment on
cell viability by clonogenic assay as shown below.
TW-37-induced cell growth inhibition by clonogenic assay
To determine the effect of TW-37 on cell growth, cells
were treated with TW-37 and assessed for cell viability by
clonogenic assay. OVCAR3, OV-90 and SKOV3DDP cells
were treated for 3 days with 250, 500, and 750 nmol/L of
TW-37. TW-37 resulted in a significant inhibition of col-
ony formation of OVCAR3, OV-90 and SKOV3DDP cells
when compared with control (Figure 4). Overall, the re-
sults from clonogenic assay was consistent with the MTT
data as shown in Figure 3B, suggesting that TW-37 inhib-
ited cell growth in OVCAR3, OV-90 and SKOV3DDP cells.
To confirm cell growth inhibition, we have also conducted
the apoptosis assay induced by TW-37.
TW-37 induced apoptosis by TUNEL and ELISA assay
OVCAR3, OV-90 and SKOV3DDP cells were treated with
250, 500 and 750 nM of TW-37 for 24–72 hr. AfterFigure 4 Effect of TW-37 on Soft-agar colony formation in OVCAR3, O
with 250, 500 and 750 nM of TW-37 for 72 hs were evaluated by the Soft-a
untreated and treated wells after 12 days. There was a significant reduction
with TW-37 compared with control cells ( the control was as 1). The experi
between cells treated by TW-37 and control using the paired t test. Vs contreatment, the degree of apoptosis was measured by
ELISA assay. We found that TW-37 induced apoptosis
in a dose- and time-dependent manner (Figure 5A). To
confirm this result, we also used TUNEL methods to de-
tect apoptosis: OVCAR3, OV-90 and SKOV3DDP cells
were treated with 750 nM of TW-37 for 72 h. TUNEL
assay also showed that TW-37 induced apoptosis in
OVCAR3, OV-90 and SKOV3DDP cells (Figure 5B).
TW-37 potentiates growth inhibition induced by DDP in
OVCAR3, OV-90 and SKOV3DDP cells
We assessed the effect of pretreatment and cotreatment
of a combination of 500 nM of TW-37 and 50 μmol/L
of cisplain on cell viability by MTT assay. Viable cells
were evaluated at 72 hs posttreatment. Pretreatment
with TW-37 for 24 hours followed by treatment with cis-
plain resulted in significant cell growth inhibition in the
three cell types investigated (Figure 6A). We next
assessed the effect of pretreatment and cotreatment of a
combination of 500 nM of TW-37 and 50 μmol/L of cis-
plain on cell viability by clonogenic assay.TW-37 re-
sulted in a significant inhibition of colony formation ofV-90 and SKOV3DDP cells. OVCAR3, OV-90 and SKOV3DDP cells treated
gar colony assay. The colonies in the soft agar were counted in all
in the colony formation in OVCAR3, OV-90 and SKOV3DDP cells treated
ments are repeated for three times. P values represent comparisons
trol, *P < 0.05; **P < 0.01.
Figure 5 Effect of TW-37 on OC cell apoptotic death. A, OVCAR3, OV-90 and SKOV3DDP cells were treated with 250, 500 and 750 nM of TW-37
for 24–72 hr. Apoptosis was measured by ELISA. B, TUNEL was performed in OVCAR3, OV-90 and SKOV3DDP cells treated with 750 nM TW-37 for
72 h using TUNEL assay. The experiments are repeated for three times. Columns, mean; bars, SD. *P < 0.05, **P < 0.01, compared with the control.
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with control (Figure 6B).
TW-37 sensitizes OVCAR3, OV-90 and SKOV3DDP cells to
apoptosis induced by DDP
Relative to single agents, pretreatment of 500 nM of
TW-37 followed by 50 μmol/L of cisplain treatment
induced much more apoptosis in the three cell lines
as shown by ELISA (Figure 6C) as well as TUNEL
analysis (Figure 6D). These results are consistent with
cell growth inhibition studies by MTT, suggesting
that the loss of viable cells by TW-37 and cisplain is
partly due to the induction of an apoptotic cell death
mechanism.Figure 6 Effect of TW-37 on cisplain induced growth inhibition and a
and SKOV3DDP cells treated with 500 nM of TW-37 combined with 50 μmo
assay (B), ELISA (C) and TUNEL assay (D). The experiments are repeated forDiscussion
The Bcl-2 family of proteins plays critical roles in human
cancers, including OC. The activation of Bcl-2 has been
shown to enhance tumor growth and inhibition of apop-
tosis. The overexpression of Bcl-2 family proteins in OC
may also play important roles in resistance to a wide
spectrum of chemotherapeutic agents [21].
Bcl-2 appears to be a compelling target for treatment
of patients with OC. Therefore, identification of an in-
hibitor targeting Bcl-2 family of proteins is likely to pro-
vide a therapeutic benefit for OC. Our current data
show that TW-37 not only inhibits cell growth and in-
duces apoptotic cell death of OC cells, but also sensi-
tized OC cells to cisplain treatment.poptosis on OVCAR3, OV-90 and SKOV3DDP cells. OVCAR3, OV-90
l/L of cisplain for 72 hs were evaluated by MTT (A), Soft-agar colony
three times.
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of Bcl-2, is capable of antagonizing the function of pan-
Bcl-2 family and thereby may have greater therapeutic
potential as an entirely new class of antitumor agent. It
has found that TW-37 inhibits the growth of a variety of
cancer cells [17,22,23]. Here, we investigated the mech-
anism by which TW-37 elicits its biological effects on
OC cells. In this study, we used bcl-2 overexpressed
OVCAR3 and OV-90 cell line, and cisplain resistant
SKOV3 cell line (SKOV3DDP). All the three cell lines
have high expression of Bcl-2 mRNA and protein. We
found that TW-37 was capable of inducing significant
growth inhibition in the cells as detected by the MTT
assay and the clonogenic assay. Moreover, TW-37 also
induced apoptotic cell death in all the cell lines, suggest-
ing that blocking Bcl-2 is sufficient to trigger apoptosis
in OC cells overexpressing the bcl-2 protein.
Whether a high level of bcl-2 gene is directly associ-
ated with resistance to DDP treatment in human OC
cells remains controversial. Our study did show a posi-
tive relationship between cisplatin sensitivity and the
level of bcl-2 in the OC cell line. In the 3AO and
SKOV3 cell lines, which has low bcl-2 mRNA and pro-
tein level, the cisplatin LD50 was around 10 μmol/L-
50 μmol/L; in the OVCAR3 and OV-90 cell lines, which
has high bcl-2 mRNA and protein level, the cisplatin
LD50 was over 100 μmol/L; In the SKOV3DDP cell line,
which has the highest bcl-2 levels, the cisplatin LD50
was over 500 μmol/L. Because cisplain treatment had no
significant effect on bcl-2 expression in mRNA and pro-
tein (data not shown) in any of the OC cells analyzed,
we therefore suggested that endogenous Bcl-2 level did
correlate with sensitivity to cisplain in OC cell line
in vitro.
Western blotting revealed that TW-37 block Bcl-2 in
all the three high blcl-2 expressed OC cells in a concen-
tration dependent and time-dependent manner. The re-
duction of bcl-2 levels correlated with the enhancement
of cisplain-induced apoptosis and growth inhibition. In
this study, we found that TW-37 pretreatment enhanced
significant tumor cell killing compared with either
agents alone. In the cisplain resistant SKOV3 cell line
( SKOV3DDP), TW-37 treatment could significantly re-
store the chemotherapy sensitivity to cisplain. Inhib-
ition of cell growth was also correlated with apoptotic
cell death. We are currently performing experiments
to evaluate in more depth possible mechanistic expla-
nations for these results. Nevertheless, these results
guided our decision to start both drugs at the same
time in our in vivo studies.
Conclusions
We presented experimental evidence, that endogenous
Bcl-2 level was positively correlated with sensitivity tocisplain in OC cell line. It also strongly supports the an-
titumor effects of TW-37 in OC in vitro. It is possible to
enhance chemosensitivity of OC cells by pretreatment
with TW-37 leading to apoptotic cell death. However,
further mechanistic studies could be useful to fully sup-
port our strategy for the treatment of patients with OC.
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